East Carolina Anesthesia Associates, PLLC
East Carolina Anesthesia Associates, PLLC was paid $3.79M by Medicaid between Jan 2018 and Dec 2024, across 47 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 25% of everything it billed.
33Billing provider infoEAST CAROLINA ANESTHESIA ASSOCIATES, PLLC
GREENVILLE, NC 27834
GREENVILLE, NC 27834
33aNPI1205996519assigned 12/11/2006
33bProvider typeRegistered Nurse
28Total paid$3.79M
24GClaims134,732
24DCodes billed47
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Registered Nurse providers in North Carolina
Rank by total paid#2 of 22
Median peer was paid$10K
This provider vs. median381×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,027 | $526K | |
| 2019 | 23,525 | $544K | |
| 2020 | 14,989 | $444K | |
| 2021 | 14,838 | $484K | |
| 2022 | 20,543 | $675K | |
| 2023 | 18,884 | $568K | |
| 2024incomplete | 16,926 | $550K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 25% | 55,386 | 39,028 | $947K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 24% | 31,547 | 23,766 | $903K |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 21% | 10,324 | 8,320 | $785K |
| 62323 | 6.0% | 4,507 | 3,234 | $229K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.7% | 4,434 | 3,456 | $217K |
| 01967 | Neuraxial labor analgesia/anesthesia for planned vaginal delivery | 5.7% | 1,462 | 1,103 | $217K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.4% | 1,222 | 1,011 | $93K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | 1.9% | 3,446 | 858 | $73K |
| 00731 | 1.4% | 2,021 | 1,605 | $53K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.3% | 1,133 | 748 | $50K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.1% | 527 | 403 | $43K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.1% | 6,147 | 3,851 | $40K |
35 more codes
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 227 | $30K |
| 00126 | <1% | 500 | $20K | |
| 00142 | <1% | 1,165 | $15K | |
| 64493 | <1% | 782 | $13K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 240 | $9K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 5,248 | $8K |
| 64494 | <1% | 729 | $6K | |
| 00790 | <1% | 33 | $4K | |
| 99152 | <1% | 1,060 | $4K | |
| 00140 | <1% | 67 | $4K | |
| 00811 | <1% | 180 | $4K | |
| 01961 | <1% | 61 | $3K | |
| 00920 | <1% | 49 | $3K | |
| 00813 | <1% | 95 | $3K | |
| 64483 | <1% | 27 | $2K | |
| 00918 | <1% | 36 | $2K | |
| 01844 | <1% | 32 | $1K | |
| 76942 | <1% | 144 | $1K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 380 | $1K |
| 27096 | <1% | 81 | $1K | |
| 99140 | <1% | 99 | $927.04 | |
| 36620 | <1% | 41 | $870.64 | |
| 64495 | <1% | 131 | $845.25 | |
| 20611 | <1% | 34 | $839.61 | |
| 00104 | <1% | 65 | $793.77 | |
| 99443 | <1% | 111 | $726.06 | |
| 99441 | <1% | 126 | $487.11 | |
| 99442 | <1% | 77 | $417.09 | |
| 20610 | <1% | 26 | $396.75 | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 15 | $351.76 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 262 | $259.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 52 | $204.46 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 53 | $153.23 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 257 | $41.58 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 91 | $32.76 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHWARTZ, JOSHUA (CHAIRMAIN)